80 related articles for article (PubMed ID: 15177234)
1. ACE inhibitors increase type III collagen synthesis: a potential explanation for reduction in acute vascular events by ACE inhibitors.
Claridge MW; Hobbs SD; Quick CR; Day NE; Bradbury AW; Wilmink AB
Eur J Vasc Endovasc Surg; 2004 Jul; 28(1):67-70. PubMed ID: 15177234
[TBL] [Abstract][Full Text] [Related]
2. Optimal medical management of peripheral arterial disease.
Rice TW; Lumsden AB
Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
[TBL] [Abstract][Full Text] [Related]
3. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study.
Rejnmark L; Vestergaard P; Mosekilde L
J Hypertens; 2006 Mar; 24(3):581-9. PubMed ID: 16467662
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials.
Volpe M; Tocci G; Sciarretta S; Verdecchia P; Trimarco B; Mancia G
J Hypertens; 2009 May; 27(5):941-6. PubMed ID: 19381108
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2.
Ekbom T; Linjer E; Hedner T; Lanke J; De Faire U; Wester PO; Dahlöf B; Scherstén B
Blood Press; 2004; 13(3):137-41. PubMed ID: 15223721
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
[TBL] [Abstract][Full Text] [Related]
8. Are antihypertensive drugs associated with abdominal aortic aneurysms?
Wilmink AB; Vardulaki KA; Hubbard CS; Day NE; Ashton HA; Scott AP; Quick CR
J Vasc Surg; 2002 Oct; 36(4):751-7. PubMed ID: 12368736
[TBL] [Abstract][Full Text] [Related]
9. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
10. [Chronic effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor enalapril on circulating procollagen marker P III NP and vascular resistance in patients with essential hypertension].
Ren YH; Liu YQ; Gai LY; Yang TS; Li TD
Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Jun; 34(6):508-11. PubMed ID: 16842666
[TBL] [Abstract][Full Text] [Related]
11. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of medical therapy for the reduction of heart failure events in patients with implanted cardioverter defibrillators.
Pietrasik G; Goldenberg I; McNitt S; Polonsky B; Moss AJ; Zareba W
J Cardiovasc Electrophysiol; 2009 Apr; 20(4):395-400. PubMed ID: 19017351
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug.
Ohta Y; Tsuchihashi T; Onaka U; Eto K; Ueno M
Hypertens Res; 2007 Apr; 30(4):301-6. PubMed ID: 17541208
[TBL] [Abstract][Full Text] [Related]
14. Class effect of angiotensin-converting enzyme inhibitors on prevention of myocardial infarction.
Sauer WH; Baer JT; Berlin JA; Kimmel SE
Am J Cardiol; 2004 Nov; 94(9):1171-3. PubMed ID: 15518614
[TBL] [Abstract][Full Text] [Related]
15. Effect of ACE inhibitors and beta-blockers on homocysteine levels in essential hypertension.
Poduri A; Kaur J; Thakur JS; Kumari S; Jain S; Khullar M
J Hum Hypertens; 2008 Apr; 22(4):289-94. PubMed ID: 18200034
[TBL] [Abstract][Full Text] [Related]
16. The impact of angiotensin-converting enzyme inhibitor therapy on the extracellular collagen matrix during left ventricular assist device support in patients with end-stage heart failure.
Klotz S; Danser AH; Foronjy RF; Oz MC; Wang J; Mancini D; D'Armiento J; Burkhoff D
J Am Coll Cardiol; 2007 Mar; 49(11):1166-74. PubMed ID: 17367660
[TBL] [Abstract][Full Text] [Related]
17. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study.
Eagle KA; Kline-Rogers E; Goodman SG; Gurfinkel EP; Avezum A; Flather MD; Granger CB; Erickson S; White K; Steg PG
Am J Med; 2004 Jul; 117(2):73-81. PubMed ID: 15234641
[TBL] [Abstract][Full Text] [Related]
18. [Effect of combined beta-blocker and angiotensin-converting enzyme inhibitor treatment on 1-year survival after acute myocardial infarction: findings of the PRIAMHO-II registry].
Arós F; Loma-Osorio A; Vila J; López-Bescós L; Cuñat J; Rodríguez E; San José JM; Heras M; Marrugat J;
Rev Esp Cardiol; 2006 Apr; 59(4):313-20. PubMed ID: 16709383
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetic interactions of three candidate gene polymorphisms with ACE-inhibitors or beta-blockers and the risk of atherosclerosis.
Schelleman H; Klungel OH; Witteman JC; Hofman A; van Duijn CM; de Boer A; Stricker BH
Br J Clin Pharmacol; 2007 Jul; 64(1):57-66. PubMed ID: 17298481
[TBL] [Abstract][Full Text] [Related]
20. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL
Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
